First-line zanidatamab plus chemotherapy leads to ‘practice-changing’ PFS and overall survival gains in a phase 3 study of ...
As Novo Nordisk launches first FDA-approved oral weight loss medication, independent examination evaluates Ro's ...
Objective: To understand patient portal engagement stratified by patient characteristics among adults 50 years and older with at least 1 common chronic medical condition using electronic health ...
Digital health equity gaps exist in patient portal engagement, even among older adults with chronic conditions who could ...
Quince Therapeutics (QNCX) rated Buy ahead of Phase 3 NEAT readout in A-T; eDSP targets $1B+ orphan market with strong cash ...
Comprehensive comparison of daily oral vs weekly injectable Wegovy following Novo Nordisk's January 2026 FDA approval of the ...
Although more women than men have pulmonary arterial hypertension, several PAH medications are teratogenic, according to a ...
Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...
The phase 3 IMforte trial(NCT05091567) demonstrated benefit for expanding on maintenance immunotherapy in extensive-stage ...
Mavacamten is a selective, reversible, allosteric cardiac myosin inhibitor. It is approved under the brand name Camzyos ® for the treatment of adults with symptomatic New York Heart Association class ...
The executive spoke at the 44 th annual 2026 JP Morgan Healthcare Conference in San Francisco early on Monday, January 12.
The third-line results build on equally compelling second-line data, where pelareorep achieved a 30% response rate, more than doubling the 13.8% benchmark for the only FDA-approved immunotherapy in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback